Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Novo Nordisk Restructures R&D, Abandons Oncology and Early-Stage MASH Programs

Novo Nordisk, the Danish pharmaceutical giant, has announced a significant restructuring of its research and development pipeline, resulting in the discontinuation of several early-stage programs and a renewed focus on its core strengths. The company's third-quarter earnings report revealed a 9 billion Danish kroner ($1.4 billion) impact from this strategic shift, which includes substantial workforce reductions and the closure of its cell therapy R&D division.

NoahAI News11/5/2025

Braveheart Bio Secures $185M for Promising Hypertrophic Cardiomyopathy Drug

Braveheart Bio has emerged as a significant player in the pharmaceutical industry with a substantial $185 million Series A funding round to advance a potentially groundbreaking treatment for hypertrophic cardiomyopathy (HCM). The startup, led by former HI-Bio CEO Travis Murdoch, is developing BHB-1893, a drug licensed from China's Hengrui Pharma that aims to challenge Bristol Myers Squibb's Camzyos in the HCM market.

NoahAI News11/5/2025

Lilly Terminates CNS Portion of $960M RIPK1 Inhibitor Collaboration with Rigel

Eli Lilly has decided to withdraw from the central nervous system (CNS) component of its $960 million collaboration with Rigel Pharmaceuticals, focusing on receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors. The announcement, made in Rigel's third-quarter earnings release, marks a significant shift in the partnership originally established in 2021.

NoahAI News11/5/2025

Novo Nordisk and Pfizer Engage in Bidding War for Metsera

In a dramatic turn of events, Novo Nordisk has entered a high-stakes bidding war with Pfizer for the acquisition of obesity biotech company Metsera. The Danish pharmaceutical giant's latest offer values Metsera at $10 billion, significantly outpacing Pfizer's initial bid of $4.9 billion plus $2.4 billion in milestone payments.

NoahAI News11/5/2025

FDA Rejects Biohaven's Troriluzole, Prompting R&D Restructuring and Raising Questions About RWE Use

The U.S. Food and Drug Administration (FDA) has rejected Biohaven Pharmaceutical's request for approval of troriluzole, a therapy intended for treating spinocerebellar ataxia, a rare neurological disorder. This decision has led the company to announce significant changes to its research and development strategy, including substantial cost-cutting measures.

NoahAI News11/5/2025

Precision Neuroscience Partners with SCI Ventures to Advance Brain-Computer Interface Technology

Precision Neuroscience, a leading developer of brain-computer interface (BCI) technology, has announced a groundbreaking partnership with SCI Ventures, a venture fund backed by major spinal cord injury organizations. This collaboration marks a significant step forward in the development of innovative solutions for individuals with paralysis and neurological conditions.

NoahAI News11/5/2025

Pfizer and Novo Nordisk Escalate Bidding War for Obesity Biotech Metsera

In a dramatic turn of events, the pharmaceutical industry is witnessing an intensifying battle between two giants, Pfizer and Novo Nordisk, for the acquisition of obesity biotech Metsera. The bidding war has not only reached unprecedented financial heights but has also spilled into the legal arena, highlighting the strategic importance of obesity therapies in the current pharmaceutical landscape.

NoahAI News11/5/2025

Novo Nordisk Outbids Pfizer in High-Stakes Battle for Obesity Biotech Metsera

The pharmaceutical industry was jolted this week as Novo Nordisk launched a surprise $10 billion bid for obesity drug developer Metsera, outmaneuvering Pfizer's previous $7.27 billion offer. This latest development has escalated into a high-profile bidding war between two pharmaceutical giants, with significant implications for the rapidly growing obesity treatment market.

NoahAI News11/5/2025

Vertex Pharmaceuticals Faces Launch Challenges Amid Pipeline Progress

Vertex Pharmaceuticals, a leading cystic fibrosis drugmaker, reported mixed results in its third-quarter earnings, with its core franchise performing well but new product launches facing headwinds. The company's shares declined 4% in pre-market trading Tuesday, reflecting investor concerns about the slow uptake of its latest offerings.

NoahAI News11/5/2025

Sarepta's DMD Treatments Face Setback as Confirmatory Study Fails to Meet Primary Endpoint

Sarepta Therapeutics, a leading biotech company in the field of Duchenne muscular dystrophy (DMD) treatment, has encountered a significant hurdle in its efforts to secure full FDA approval for two of its exon-skipping therapies. The company's Phase III ESSENCE trial, designed to confirm the efficacy of Vyondys 53 and Amondys 45, failed to demonstrate a statistically significant improvement in motor function among DMD patients.

NoahAI News11/5/2025

Blackstone Invests $700M in Merck's Antibody-Drug Conjugate Program

In a significant move within the pharmaceutical industry, Blackstone Life Sciences has announced a $700 million investment in Merck & Co.'s antibody-drug conjugate (ADC) program. This deal, revealed on Tuesday, marks a substantial commitment to the burgeoning field of ADCs and underscores the growing interest in targeted cancer therapies.

NoahAI News11/5/2025

Questex Acquisition Bolsters Fierce Portfolio with The Conference Forum and Versalinx Global Events

In a strategic move set to reshape the landscape of life sciences media and events, Questex has announced the acquisition of The Conference Forum and Versalinx Global Events. This significant expansion of Questex's Healthcare & Life Sciences portfolio promises to enhance the company's ability to connect industry leaders, foster innovation, and accelerate business growth across the pharmaceutical and healthcare sectors.

NoahAI News11/5/2025

«1...42 43 44...67 »